ValueQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSelling/general/admin expenses2.04 M2.23 M2.06 M3 M2.44 M9.72 MResearch & development2.97 M3.2 M3.11 M6.36 M1.88 M14.55 M영업 이익-5 M-5.43 M-5.17 M-9.36 M-4.32 M-24.27 MNon-Operating Income, Total159.6 K82.18 K79.7 K78.43 K73.65 K313.95 KInterest expense, net of interest capitalized-28—————Non-Operating Income, excl. Interest Expenses79.81 K82.18 K79.7 K00161.88 KUnusual income/expense79.81 K——78.43 K73.65 K—Pretax income-4.85 M-5.34 M-5.09 M-9.28 M-22.39 M-42.1 MEquity in earnings——————Taxes—0002 0002 000Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations-3.57 M-4.52 M-5.35 M-8.9 M-3.63 M-22.4 MDiscontinued operations——————Net income-3.57 M-4.52 M-5.35 M-8.9 M-3.63 M-22.4 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders-3.57 M-4.52 M-5.35 M-8.9 M-3.63 M-22.4 MBasic earnings per share (Basic EPS)-0.08-0.16-0.18-0.27-0.09-0.7Diluted earnings per share (Diluted EPS)-0.08-0.16-0.18-0.27-0.09-0.7Average basic shares outstanding22.2 M27.7 M30.3 M33.2 M32.11 M123.31 MDiluted shares outstanding22.2 M27.7 M30.3 M33.2 M32.11 M123.31 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)——————
MAIA Biotechnology Inc
MAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.